Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension

Journal of Human Hypertension

Volumn 30, Issue 1, 2016, Pages 35-39

  Petrak O ^a   Zelinka, T ^a   Strauch B ^a   Rosa, J ^a   Somloova Z ^a   Indra, T ^a   Turkova H ^a   Holaj, R ^a   Widimsky J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL MUSCLE RELAXANT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; METIPAMIDE; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; URAPIDIL;

ADULT; ANAMNESIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL PRACTICE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UNCONTROLLED HYPERTENSION; COMBINATION DRUG THERAPY; CZECH REPUBLIC; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CZECH REPUBLIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84949109684     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.24     Document Type: Article

References (30)

1. Cífková R, Škodová Z, Bruthans J, Holub J, Adámková V, Jozífová M, et al. Longitudinal trends in cardiovascular mortality, and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010; 28(11): 2196-2203
2. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health, and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. Centers for Disease Control, and Prevention: Hyattsville, MD, USA. Number 133, October 2013; pp 1-8
3. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment, and control in national surveys from England, the USA, and Canada, and correlation with stroke, and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013; 3(8): e003423
4. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic highrisk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17(5): 530-540
5. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH), and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357
6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403-1419
7. Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011; 58(6): 1008-1013
8. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57(6): 1076-1080
9. Rosa J, Zelinka T, Petrák O, Štrauch B, Šomlóová Z, Indra T, et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? J Hum Hypertens 2014; 28 (11): 684-688
10. Štrauch B, Zelinka T, Hampf M, Bernhardt R, Widimský J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17(5): 349-352
11. Mancia G, De Backer G, Dominiczak A, Cífková R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25(9): 1751-1762
12. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009; 361(22): 2153-2164
13. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996; 30(3): 229-249
14. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56(19): 1527-1534
15. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30(8): 1656-1664
16. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55(1): 147-152
17. Václavík J, Sedlák R, Plachý M, Navratil K, Plášek J, Jarkovský J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57(6): 1069-1075
18. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49(4): 839-845
19. Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure, and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118(1): 42-48
20. Black HR, Keck M, Meredith P, Bullen K, Quinn S, Koren A. Controlled-release doxazosin as combination therapy in hypertension: the GATES study. J Clin Hypertens 2006; 8(3): 159-166 quiz 167-8
21. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive, and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283(15): 1967-1975
22. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372(9638): 547-553
23. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121-2158
24. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367(23): 2204-2213
25. Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, et al. Effects of dual blockade of the renin-angiotensin system on renal, and cardiovascular outcomes in type 2 diabetes with overt nephropathy, and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res 2013; 36(12): 1051-1059
26. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369(20): 1892-1903
27. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, et al. Triple pharmacological blockade of the reninangiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52(3): 486-493
28. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor, and angiotensin II receptor blocker. Hypertens Res 2008; 31(1): 59-67
29. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28(11): 2329-2335
30. Buch J. Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther 2010; 27(7): 426-443